Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo

Kenneth C. Haltalin, John D. Nelson, Robert Ring, Mildred Sladoje, Lula V. Hinton

Research output: Contribution to journalArticlepeer-review

78 Scopus citations

Abstract

A double-blind treatment study comparing ampicillin, sulfadiazine, and placebo was performed in 52 infants and children hospitalized for shigellosis. Bacteriological failure rates in patients treated with placebo and sulfadiazine were 75 per cent and 39 per cent, respectively, compared with 6 per cent in ampicillin-treated patients. Clinical failure occurred in 56 per cent of patients treated with placebo, 39 per cent in sulfadiazine-treated patients and in none of the patients who received ampicillin. Ampicillin is a safe and highly effective drug for the treatment of shigellosis.

Original languageEnglish (US)
Pages (from-to)970-981
Number of pages12
JournalThe Journal of pediatrics
Volume70
Issue number6
DOIs
StatePublished - Jun 1967

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of 'Double-blind treatment study of shigellosis comparing ampicillin, sulfadiazine, and placebo'. Together they form a unique fingerprint.

Cite this